SheVari4

Raktim Chattopadhyay, Subhankar Karmakar, Tandra R Chakraborty, Manashi Bagchi, Samudra P Banik, Debasis Bagchi

Abstract read

In one paragraph

Article in Food & nutrition research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it

0cells of the map it votes in

1citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

Unraveling the Mechanistic Insights ofNutrients · 2026
Review

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Raktim ChattopadhyayEsperer Onco Nutrition Pvt Ltd, Thane, Navi Mumbai, Maharashtra, India.

Subhankar KarmakarLakshya Hospital, Pune, Maharashtra, India.

Tandra R ChakrabortyBiology Department, College of Arts and Sciences, Adelphi University, Garden City, NY, USA.

Manashi BagchiResearch & Development Department, Dr. Herbs LLC, Concord, CA, USA.

Samudra P BanikDepartment of Microbiology, Government General Degree College, Narayangarh, Rathipur, West Bengal, India.

Debasis BagchiBiology Department, College of Arts and Sciences, Adelphi University, Garden City, NY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Objective: Menopause marks the natural end of reproductive phase of women caused by decline in levels of estrogen, progesterone and other reproductive hormones. Methodology: Sixty women (age 50.0 ± 7.4 years) randomized in two equal groups were administered with 100 mg SheVari4 Results: SheVari4 induced a 42.8% reduction in MENQOL versus placebo. Significant improvements in functioning (vs. placebo) were observed, respectively, across vasomotor (53.1% vs. 14.5%), psychosocial (53.6% vs. 9.9%), physical (39.2% vs. 6.5%) and sexual (29.4% vs. 10.7%) domains. The formulation also increased E2 (+36.44% vs. -2.08%) and progesterone (+0.30% vs. -2.88%) coupled with marked reduction in levels of FSH (-38.18% vs. +12.97%) and cortisol (-26.87% vs. +17.16%). Concomitantly, AMH, SHBG, and free testosterone were also favorably modulated. Blood biochemistry, liver function tests, and vital signs confirmed the broad-spectrum safety of SheVari4 Conclusion: SheVari4

Indexed as

Asparagus racemosusendocrine balanceMenopausal Quality of Lifepsychosocial wellbeingShatavarin IVSheVari4®

Identifiers

PMID42571384

DOI10.29219/fnr.v70.14275

PMCPMC13452268

What Socratic holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.